NASDAQ:TRAW Traws Pharma (TRAW) Stock Price, News & Analysis → America’s worst nightmare? (From Porter & Company) (Ad) Free TRAW Stock Alerts $0.65 0.00 (0.00%) (As of 05/13/2024 ET) Add Compare Share Share Today's Range$0.63▼$0.6750-Day Range N/A52-Week Range$0.55▼$1.33Volume29,321 shsAverage Volume102,631 shsMarket Capitalization$16.33 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsOptions ChainSEC FilingsSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsOptions ChainSEC FilingsSocial Media Get Traws Pharma alerts: Email Address Ad InvestorPlaceCrypto Millionaire Says: “Buy This $11 AI Coin.”Right now, you can harness the power of two bull markets... Artificial intelligence...And cryptos.Find out more about this $11 AI Coin right now About Traws PharmaTraws Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for patients with check point inhibitor (CPI) resistant K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China; with SymBio Pharmaceuticals Limited for the development and commercialization of rigosertib in Japan and Korea; and Pint License Agreement to develop and commercialize any pharmaceutical product containing rigosertib in all uses of rigosertib in humans in Latin American countries. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.Read More TRAW Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TRAW Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com Receive TRAW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Traws Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/01/2024Today5/13/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TRAW CUSIPN/A CIK1130598 Webwww.onconova.com Phone267-759-3680Fax267-759-3681Employees17Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,950,000.00 Net Margins-8,384.07% Pretax Margin-8,384.07% Return on Equity-113.18% Return on Assets-65.76% Debt Debt-to-Equity RatioN/A Current Ratio2.46 Quick Ratio2.46 Sales & Book Value Annual Sales$230,000.00 Price / Sales71.02 Cash FlowN/A Price / Cash FlowN/A Book Value$0.51 per share Price / Book1.27Miscellaneous Outstanding Shares25,300,000Free Float24,466,000Market Cap$16.33 million OptionableOptionable Beta1.43 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Steven M. Fruchtman M.D. (Age 73)President & Chief Scientific Officer of Oncology Comp: $907.86kMr. Mark Patrick Guerin CPA (Age 55)Chief Financial Officer Comp: $629.27kDr. Iain D. Dukes DPHIL (Age 66)M.A., Ph.D., Executive Chairman Dr. Werner Cautreels Ph.D. (Age 72)CEO & Director Dr. Nikolay Savchuk Ph.D. (Age 55)COO & Director Dr. Victor Moyo M.D.Chief Medical OfficerRobert Redfield M.D.Acting Chief Medical OfficerCharles David Pauza Ph.D.Chief Scientific Officer of VirologyMore ExecutivesKey CompetitorsMinerva NeurosciencesNASDAQ:NERVCocrystal PharmaNASDAQ:COCPTonix PharmaceuticalsNASDAQ:TNXPVaxxinityNASDAQ:VAXXNanoViricidesNYSE:NNVCView All Competitors TRAW Stock Analysis - Frequently Asked Questions How have TRAW shares performed in 2024? Traws Pharma's stock was trading at $0.8081 at the beginning of 2024. Since then, TRAW shares have decreased by 20.1% and is now trading at $0.6456. View the best growth stocks for 2024 here. When is Traws Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our TRAW earnings forecast. How were Traws Pharma's earnings last quarter? Traws Pharma, Inc. (NASDAQ:TRAW) announced its earnings results on Monday, April, 1st. The company reported ($0.20) earnings per share for the quarter. The business had revenue of $0.06 million for the quarter. Traws Pharma had a negative net margin of 8,384.07% and a negative trailing twelve-month return on equity of 113.18%. How do I buy shares of Traws Pharma? Shares of TRAW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TRAW) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersGuard Against the Coming Financial UpheavalPorter & CompanyElon’s New Device is About to Shock the WorldInvestorPlaceConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressCharles Payne Demystifies OptionsUnstoppable ProsperityThe only AI company you should be looking atBehind the MarketsGold ManiaStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Traws Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.